Home > Insider Trading > Filing (0001181431-13-033514)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219871	M David Mott	1954 Greenspring Drive Suite 600 Timonium MD 21093		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-06-05	5,633,240	$0.00	5,633,240	No	4	C	Indirect	See Note 2
Common Stock	Acquisiton	2013-06-05	400,000	$15.00	6,033,240	No	4	P	Indirect	See Note 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Note 2
No	4	P	Indirect	See Note 2

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2013-06-05	16,899,721	$0.00	5,633,240	$0.00
Common Stock	Director Stock Option (Right to Buy)	Acquisiton	2013-06-05	17,666	$0.00	17,666	$25.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
17,666		2023-06-04	No	4	A	Direct

Footnotes

Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of Common Stock of the Issuer, upon the closing of the Issuer's initial public offering without payment of further consideration and had no expiration date.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the securities held by NEA 13, except to the extent of his pecuniary interest therein.
Vests in full upon the earlier of (i) the expiration of the Reporting Person's initial term of office as a director of the Issuer, scheduled to occur on the 2016 annual meeting of the Issuer's stockholders and (ii) June 30, 2016. In the event of a change in control of the Issuer, the vesting schedule of the option will accelerate in full.